Invention Grant
US08092807B2 Modified leukocyte Ig-like receptor family members (LIRs) with increased affinity for class 1 MHC and their uses in modulating T-cell activation
失效
具有增加的1 MHC的亲和力及其在调节T细胞活化中的用途的改良的白细胞Ig样受体家族成员（LIR）
- Patent Title: Modified leukocyte Ig-like receptor family members (LIRs) with increased affinity for class 1 MHC and their uses in modulating T-cell activation
- Patent Title (中): 具有增加的1 MHC的亲和力及其在调节T细胞活化中的用途的改良的白细胞Ig样受体家族成员（LIR）
-
Application No.: US11914175Application Date: 2006-05-19
-
Publication No.: US08092807B2Publication Date: 2012-01-10
- Inventor: Bent Karsten Jakobsen , Yi Li , Ruth Karen Moysey
- Applicant: Bent Karsten Jakobsen , Yi Li , Ruth Karen Moysey
- Applicant Address: DE Martinsried
- Assignee: MediGene AG
- Current Assignee: MediGene AG
- Current Assignee Address: DE Martinsried
- Agency: Banner & Witcoff, Ltd.
- Priority: GB0510627.3 20050525
- International Application: PCT/GB2006/001860 WO 20060519
- International Announcement: WO2006/125963 WO 20061130
- Main IPC: A61K39/00
- IPC: A61K39/00
Abstract:
The present invention provides polypeptides having the property of binding to a given Class I pMHC CHARACTERISED IN THAT said polypeptide has a KD for the said given Class I pMHC of less than or equal to 1 μM and/or has an off-rate (koff) for the said given Class I pMHC molecule of 2 S−1 or slower AND said polypeptide has at least a 45% identity and/or 55% similarity to a defined high-affinity ILT-like molecule AND said polypeptide inhibits CD8 binding to the given pMHC to a greater extent than a soluble truncated variant of Wild-Type ILT-2. Such high-affinity ILT-like molecules are useful, either alone or associated with a therapeutic agent, for the inhibition of cytotoxic T cell (CTL) responses.
Public/Granted literature
- US20090208447A1 Polypeptides Public/Granted day:2009-08-20
Information query
